메뉴 건너뛰기




Volumn 46, Issue 3, 2010, Pages 541-548

Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias

Author keywords

Cross trial comparisons; Historical comparisons; Randomised trials; Statistical models; Treatment efficacy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PREDNISONE;

EID: 75149163309     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.11.013     Document Type: Article
Times cited : (11)

References (32)
  • 1
    • 0033128807 scopus 로고    scopus 로고
    • Statistics notes: Treatment allocation in controlled trials: why randomise?
    • Altman D.G., and Bland J.M. Statistics notes: Treatment allocation in controlled trials: why randomise?. Br Med J 318 7192 (1999) 1209
    • (1999) Br Med J , vol.318 , Issue.7192 , pp. 1209
    • Altman, D.G.1    Bland, J.M.2
  • 2
    • 58049217470 scopus 로고    scopus 로고
    • Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer
    • Mauri D., Polyzos N.P., Salanti G., Pavlidis N., and Ioannidis J.P.A. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100 24 (2008) 1780-1791
    • (2008) J Natl Cancer Inst , vol.100 , Issue.24 , pp. 1780-1791
    • Mauri, D.1    Polyzos, N.P.2    Salanti, G.3    Pavlidis, N.4    Ioannidis, J.P.A.5
  • 3
    • 0013573468 scopus 로고
    • The role of statistics in the design and evaluation of trials in cancer medicine
    • Veronesi U., and Bonadonna G. (Eds), Academic Press, Orlando
    • Zelen M. The role of statistics in the design and evaluation of trials in cancer medicine. In: Veronesi U., and Bonadonna G. (Eds). Clinical trials in cancer medicine (1985), Academic Press, Orlando 561-568
    • (1985) Clinical trials in cancer medicine , pp. 561-568
    • Zelen, M.1
  • 4
    • 34248359393 scopus 로고    scopus 로고
    • The dangers of "cross-trial" and "cross-retrospective experience" comparisons
    • Markman M. The dangers of "cross-trial" and "cross-retrospective experience" comparisons. Cancer 109 (2007) 1929-1932
    • (2007) Cancer , vol.109 , pp. 1929-1932
    • Markman, M.1
  • 5
    • 0023617472 scopus 로고
    • Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
    • Coates A., Gebski V., Bishop J., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. New Engl J Med 317 24 (1987) 1490-1495
    • (1987) New Engl J Med , vol.317 , Issue.24 , pp. 1490-1495
    • Coates, A.1    Gebski, V.2    Bishop, J.3
  • 6
    • 0344606138 scopus 로고
    • Quality of life with single agent mitozantrone or combination chemotherapy for advanced breast cancer, a randomised trial
    • Simes R., Gebski V., Coates A., et al. Quality of life with single agent mitozantrone or combination chemotherapy for advanced breast cancer, a randomised trial. Proc Am Soc Clin Oncol 13 (1994) 73
    • (1994) Proc Am Soc Clin Oncol , vol.13 , pp. 73
    • Simes, R.1    Gebski, V.2    Coates, A.3
  • 7
    • 34548228450 scopus 로고    scopus 로고
    • A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment
    • Stockler M., Sourjina T., Harvey V., et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Res Treat 100 (2007) S278
    • (2007) Breast Cancer Res Treat , vol.100
    • Stockler, M.1    Sourjina, T.2    Harvey, V.3
  • 9
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 3 (2000) 205-216
    • (2000) J Natl Cancer Inst , vol.92 , Issue.3 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 10
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 282 (1958) 457-481
    • (1958) J Am Stat Assoc , vol.53 , Issue.282 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 11
    • 0000336139 scopus 로고
    • Regression models and life-tables
    • Cox D.R. Regression models and life-tables. J Roy Stat Soc 34 2 (1972) 187-220
    • (1972) J Roy Stat Soc , vol.34 , Issue.2 , pp. 187-220
    • Cox, D.R.1
  • 13
    • 0037301972 scopus 로고    scopus 로고
    • Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor
    • Chang J., Clark G., Allred D., et al. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97 (2003) 545-553
    • (2003) Cancer , vol.97 , pp. 545-553
    • Chang, J.1    Clark, G.2    Allred, D.3
  • 14
    • 0035138906 scopus 로고    scopus 로고
    • Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy
    • Ryberg M., Nielsen D., Osterlind K., Skovsgaard T., and Dombernowsky P. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 12 1 (2001) 81-87
    • (2001) Ann Oncol , vol.12 , Issue.1 , pp. 81-87
    • Ryberg, M.1    Nielsen, D.2    Osterlind, K.3    Skovsgaard, T.4    Dombernowsky, P.5
  • 15
    • 56749175264 scopus 로고    scopus 로고
    • Prognostic factors in 1038 women with metastatic breast cancer
    • Largillier R., Ferrero J.-M., Doyen J., et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol (2008) mdn424
    • (2008) Ann Oncol
    • Largillier, R.1    Ferrero, J.-M.2    Doyen, J.3
  • 16
    • 26444607816 scopus 로고    scopus 로고
    • Survival of metastatic breast carcinoma patients over a 20-year period
    • Gennari A., Conte P., Rosso R., Orlandini C., and Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period. Cancer 104 8 (2005) 1742-1750
    • (2005) Cancer , vol.104 , Issue.8 , pp. 1742-1750
    • Gennari, A.1    Conte, P.2    Rosso, R.3    Orlandini, C.4    Bruzzi, P.5
  • 17
    • 0021050287 scopus 로고
    • Multivariate analysis of prognostic factors in metastatic breast cancer
    • Hortobagyi G., Smith T., Legha S., et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1 (1983) 776-786
    • (1983) J Clin Oncol , vol.1 , pp. 776-786
    • Hortobagyi, G.1    Smith, T.2    Legha, S.3
  • 18
    • 0031830823 scopus 로고    scopus 로고
    • Construction and validation of a practical prognostic index for patients with metastatic breast cancer
    • Yamamoto N., Watanabe T., Katsumata N., et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16 7 (1998) 2401-2408
    • (1998) J Clin Oncol , vol.16 , Issue.7 , pp. 2401-2408
    • Yamamoto, N.1    Watanabe, T.2    Katsumata, N.3
  • 19
    • 0031038467 scopus 로고    scopus 로고
    • An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting
    • Jantunen I.T., Kataja V.V., and Muhonen T.T. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33 1 (1997) 66-74
    • (1997) Eur J Cancer , vol.33 , Issue.1 , pp. 66-74
    • Jantunen, I.T.1    Kataja, V.V.2    Muhonen, T.T.3
  • 20
    • 0027517374 scopus 로고
    • Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group
    • Seshadri R., Firgaira F., Horsfall D., et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11 10 (1993) 1936-1942
    • (1993) J Clin Oncol , vol.11 , Issue.10 , pp. 1936-1942
    • Seshadri, R.1    Firgaira, F.2    Horsfall, D.3
  • 21
    • 0024337144 scopus 로고
    • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    • Slamon D., Godolphin W., Jones L., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
    • (1989) Science , vol.244 , Issue.4905 , pp. 707-712
    • Slamon, D.1    Godolphin, W.2    Jones, L.3
  • 22
    • 33947645465 scopus 로고    scopus 로고
    • Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?
    • Dunkler D., Michiels S., and Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer 43 4 (2007) 745-751
    • (2007) Eur J Cancer , vol.43 , Issue.4 , pp. 745-751
    • Dunkler, D.1    Michiels, S.2    Schemper, M.3
  • 23
    • 42949145995 scopus 로고    scopus 로고
    • Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    • Burzykowski T., Buyse M., Piccart-Gebhart M.J., et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26 12 (2008) 1987-1992
    • (2008) J Clin Oncol , vol.26 , Issue.12 , pp. 1987-1992
    • Burzykowski, T.1    Buyse, M.2    Piccart-Gebhart, M.J.3
  • 24
    • 53149130962 scopus 로고    scopus 로고
    • Progression-free survival as a surrogate endpoint in advanced breast cancer
    • Miksad R.A., Zietemann V., Gothe R., et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Tech Assess Health Care 24 04 (2008) 371-383
    • (2008) Int J Tech Assess Health Care , vol.24 , Issue.4 , pp. 371-383
    • Miksad, R.A.1    Zietemann, V.2    Gothe, R.3
  • 25
    • 0037374008 scopus 로고    scopus 로고
    • Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses
    • Song F., Altman D., Glenny A., and Glenny J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 326 7387 (2003) 472-477
    • (2003) Br Med J , vol.326 , Issue.7387 , pp. 472-477
    • Song, F.1    Altman, D.2    Glenny, A.3    Glenny, J.4
  • 26
    • 0020045659 scopus 로고
    • Randomized versus historical controls for clinical trials
    • Sacks H., Chalmers T., and Smith H. Randomized versus historical controls for clinical trials. Am J Med 72 (1981) 233-240
    • (1981) Am J Med , vol.72 , pp. 233-240
    • Sacks, H.1    Chalmers, T.2    Smith, H.3
  • 27
    • 0032585188 scopus 로고    scopus 로고
    • The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials
    • Kunz R., and Oxman A. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. Br Med J 317 (1998) 1185-1190
    • (1998) Br Med J , vol.317 , pp. 1185-1190
    • Kunz, R.1    Oxman, A.2
  • 28
    • 24644519961 scopus 로고    scopus 로고
    • Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the italian tamoxifen anastrozole trial
    • Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the italian tamoxifen anastrozole trial. J Clin Oncol 23 22 (2005) 5138-5147
    • (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 5138-5147
    • Boccardo, F.1    Rubagotti, A.2    Puntoni, M.3
  • 29
    • 69049113989 scopus 로고    scopus 로고
    • Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
    • The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New Engl J Med 361 8 (2009) 766-776
    • (2009) New Engl J Med , vol.361 , Issue.8 , pp. 766-776
    • The BIG 1-98 Collaborative Group1
  • 30
    • 33748563196 scopus 로고    scopus 로고
    • Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel
    • Ozols R., Bookman M., du Bois A., et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103 1 (2006) 1-6
    • (2006) Gynecol Oncol , vol.103 , Issue.1 , pp. 1-6
    • Ozols, R.1    Bookman, M.2    du Bois, A.3
  • 31
    • 33847152253 scopus 로고    scopus 로고
    • When are randomised trials unnecessary? Picking signal from noise
    • Glasziou P., Chalmers I., Rawlins M., and McCulloch P. When are randomised trials unnecessary? Picking signal from noise. Br Med J 334 7589 (2007) 349-351
    • (2007) Br Med J , vol.334 , Issue.7589 , pp. 349-351
    • Glasziou, P.1    Chalmers, I.2    Rawlins, M.3    McCulloch, P.4
  • 32
    • 66749086365 scopus 로고    scopus 로고
    • The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?
    • Howick J., Glasziou P., and Aronson J.K. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?. J Roy Soc Med 102 5 (2009) 186-194
    • (2009) J Roy Soc Med , vol.102 , Issue.5 , pp. 186-194
    • Howick, J.1    Glasziou, P.2    Aronson, J.K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.